By Dennis Thompson HealthDay Reporter
SATURDAY, March 13, 2021
About 7 out of 10 Alzheimer’s clients wound up cost-free of the brain plaques that are a hallmark of the condition immediately after treatment with a most likely breakthrough experimental drug, scientific demo results present.
The drug, donanemab, also noticeably slowed the patients’ mind drop, in accordance to conclusions revealed March 13 in the New England Journal of Drugs.
Donanemab dissolves long-lasting plaque deposits of amyloid-beta, the harmful sticky protein that accumulates in the brains of men and women with Alzheimer’s, explained review co-author Dr. Liana Apostolova, a professor of Alzheimer’s illness analysis at Indiana University College of Drugs.
The stage 2 scientific demo involved 257 people, about 50 percent of whom obtained intravenous donanemab just about every 4 weeks for up to a yr and a half. The other fifty percent been given a placebo.
“The drug was very